Investor Presentaiton

Expanding opportunity Significant capital needs Innovative funding Facilitating M&A Differentiated sourcing Significant opportunity to fund biopharma innovation Biopharma ecosystem cumulative R&D spend over next decade Global pharma market (2) >$1 trillion(1) Third-party royalties by academic, Third-party royalties Synthetic royalties non-profits $1.6 trillion by profitable pharmas $1.1 trillion by unprofitable biotechs (including SG&A) Synthetic royalties, Third-party royalties $2.3 trillion Biopharma revenues (2030e) launch & development capital $1.3 trillion Revenues from currently unapproved therapies ROYALTY PHARMA Entire biopharma ecosystem drives our pipeline Source: Bloomberg, Visible Alpha and CaplQ 1. Based on estimates from Research America and internal Royalty Pharma analysis. 2. Based on Evaluate Pharma as of May 2022. 36

View entire presentation